Titan Medical
TMDI

From December 31, 2020 to December 31, 2021 Derivative warrants exercised Derivative warrants exercised–fair value adjustment January 2021 equity offering, net of issuance costs January 2021 equity offering, broker warrants February 2021 equity offering, net of issuance costs February 2021 equity offering, broker warrants Equity warrants exercised Stock options exercised Sale of common shares to Aspire Issuance of common shares to consultant

From December 31, 2020 to June 30, 2021 Derivative warrants exercised January 2021 Equity Offering, net of issuance costs February 2021 Equity Offering, net of issuance costs Equity warrants exercised Options exercised Issuance of common shares

From December 31, 2020 to March 31, 2021 Derivative warrants exercised January 2021 Equity Offering, net of issuance costs February 2021 Equity Offering, net of issuance costs Equity warrants exercised Options exercised

1.Titan Medical Inc. announced today that it closed its previously announced offering of 8,335,000 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of US $20,004,000 (the “Offering”). Bloom Burton Securities Inc. acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 1,250,250 Units and additional gross proceeds to the Company of US $3,000,600. Each Unit was issued at a price of US $2.40 per Unit and consisted of one common share in the capital of the Company (each a “Common Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “Warrant”).

1.Titan Medical Inc. announced today that it closed its previously announced offering of 6,451,613 units of the Company (“Units”) sold on a “bought deal” basis for gross proceeds of approximately US $10,000,000.00 (the “Offering”). Bloom Burton Securities Inc. (the “Underwriter”) acted as underwriter for the Offering and exercised its over-allotment option in full on the date hereof for an additional 967,741 Units and additional gross proceeds to the Company of approximately US $1,500,000.

From December 31, 2019 to December 31, 2020 Issued pursuant to agency agreement Common stock equivalents converted Warrants exercised during the year

From December 31, 2019 to September 30, 2020 Issued pursuant to agency agreement Common stock equivalents converted Warrants exercised during the period

From March 31, 2020 to June 30, 2020 Issued pursuant to agency agreement Share issue expense Common stock equivalents converted Warrants exercised during the period

1.Securities Offered 6,500,000 Common Shares, 11,500,000 Pre-Funded Warrants, and Common Warrants to purchase 9,000,000 Common Shares. 2.The number of Common Shares to be outstanding immediately after completion of the Offering as shown above is based on 60,831,381 Common Shares outstanding as of June 8, 2020 and assumes the full exercise of the Pre-Funded Warrants.

from December 31, 2019 to March 31, 2020 Issued pursuant to agency agreement Warrants exercised during the period

from December 31, 2018 to December 31, 2019 Issued pursuant to agency agreement Warrants exercised during the year Issued pursuant to private placements

from December 31, 2018 to March 31, 2019 Issued pursuant to agency agreement Warrants exercised during the year

From December 31, 2017 to August 10, 2018 Issued pursuant to agency agreement Issued Other Warrants exercised during the year

from December 31, 2017 to June 30, 2018 Issued pursuant to agency agreement Issued Other Warrants exercised during the period